Motivation-Phase Nicotine Mini-Lozenge — Competitive Intelligence Brief

Motivation-Phase Nicotine Mini-Lozenge (Motivation-Phase Nicotine Mini-Lozenge) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic acetylcholine receptor agonist. Area: Addiction Medicine / Smoking Cessation.

marketed Nicotinic acetylcholine receptor agonist Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule

Target snapshot

Motivation-Phase Nicotine Mini-Lozenge (Motivation-Phase Nicotine Mini-Lozenge) — VA Office of Research and Development. Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Motivation-Phase Nicotine Mini-Lozenge TARGET	Motivation-Phase Nicotine Mini-Lozenge	VA Office of Research and Development	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Usual brand cigar	Usual brand cigar	Ohio State University Comprehensive Cancer Center	marketed		nicotinic acetylcholine receptors
patch + lozenge	patch + lozenge	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
nicotine patch, labeled use	nicotine patch, labeled use	University of Vermont	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine Patch + Nicotine Gum	Nicotine Patch + Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Chantix	Varenicline Tartrate	Pfizer Inc.	marketed	Nicotinic receptor partial agonist	α4β2 neuronal nicotinic acetylcholine receptors
NRT (NicoDerm CQ)	NRT (NicoDerm CQ)	University of California, San Francisco	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2035-10-19 — Chantix · 11224598 · Method of Use · US
• 2035-10-19 — Chantix · 10456396 · Formulation · US
• 2035-10-19 — Chantix · 9597284 · Method of Use · US
• 2035-10-19 — Chantix · 9532944 · Method of Use · US
• 2035-10-19 — Chantix · 9504644 · Method of Use · US
• 2035-10-19 — Chantix · 11911380 · Method of Use · US
• 2035-10-19 — Chantix · 11903943 · Method of Use · US
• 2035-10-19 — Chantix · 11903941 · Method of Use · US
• 2035-10-19 — Chantix · 9504645 · Formulation · US
• 2035-10-19 — Chantix · 11903942 · Formulation · US

Sponsor landscape (Nicotinic acetylcholine receptor agonist class)

1. University of Wisconsin, Madison · 3 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. VA Office of Research and Development · 2 drugs in this class
4. Iowa City Veterans Affairs Medical Center · 1 drug in this class
5. Johns Hopkins University · 1 drug in this class
6. Medical University of Vienna · 1 drug in this class
7. 22nd Century Group, Inc. · 1 drug in this class
8. University of Auckland, New Zealand · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class
10. University of Miami · 1 drug in this class